Encora Therapeutics is excited to announce the successful completion of the ULTRE (Upper Limb Tremor Reduction in Essential Tremor) clinical trial. The study assessed the safety, tolerability, and effectiveness of Encora’s innovative wrist-worn stimulation device for individuals with essential tremor (ET). ET is a common movement disorder that impacts the upper limbs of an estimated 7.6 million Americans. Current treatments for ET often fall short in effectiveness and can be poorly tolerated, highlighting the urgent need for new, more effective therapeutic options.
Encora Therapeutics is proud to announce the successful completion of the ULTRE (Upper Limb Tremor Reduction in Essential Tremor) clinical trial, evaluating the safety, tolerability, and effectiveness of its wrist-worn stimulation device for patients with essential tremor (ET). ET affects an estimated 7.6 million Americans, and current treatment options remain limited, highlighting the critical need for new therapies.
The 47-patient ULTRE study was a double-blind, randomized, sham-controlled, cross-over trial, designed to meet high scientific standards. Two different vibrotactile stimulation approaches—Pulsed and Continuous—were tested against an inactive sham control. Strict inclusion criteria were applied to ensure the study’s scientific rigor and clinical relevance.
The trial’s primary endpoints focused on assessing the safety and tolerability of the device, while secondary endpoints examined changes in motor function and the ability to perform daily tasks, providing a comprehensive evaluation of the device’s impact on patients. Tremor severity was measured using validated clinical scales, including the Essential Tremor Rating Assessment Scale (TETRAS) and the Bain & Findley Activities of Daily Living (BF-ADL) scale. These assessments were completed by blinded, experienced raters and through patient self-report, ensuring robust and objective data collection.
Dr. Rodger Elble, a study investigator, commented, “The ULTRE study design is exceptionally rigorous and well-suited for evaluating a therapeutic for Essential Tremor.”
Dr. Fatta B. Nahab, Principal Investigator of the study, added, “Enrollment in the ULTRE study progressed quickly, demonstrating a strong demand and need for novel treatments in the Essential Tremor community. The Encora device has shown excellent safety and tolerability, which is a promising step forward for this pioneering technology and brings new hope to patients.”
Daniel Carballo, CEO of Encora Therapeutics, stated, “The completion of the ULTRE trial with encouraging results marks a key milestone in our efforts to develop non-invasive, innovative solutions for patients with Essential Tremor. We look forward to sharing the full results in an upcoming publication.”
About Encora Therapeutics
Encora Therapeutics is a leader in wearable neuromodulation technology, dedicated to developing non-invasive treatments to improve the lives of individuals with movement disorders, including Essential Tremor.
